Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Cardiac Biomarkers Market, by Product Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), and Others), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), by Location of Testing (Laboratory Testing and Point-of-Care Testing), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4,869.2 million in 2021, and is expected to exhibit a CAGR of 10.4% during the forecast period (2021-2028).

Rising cases of cardiovascular diseases is expected to drive growth of the global cardiac biomarkers market during the forecast period. For instance, according to an article published by the National Centers for Biotechnology Information in July 2020, there is an increasing prevalence of Ischemic heart disease across the globe, as it affects 1,655 per 100,000 individuals, which may rise up to 1,845 per 100,000 individuals by the year 2030.

Private and government initiatives for funding the research and development activities for cardiovascular diseases management is expected to fuel the market growth of cardiac biomarkers over the forecast period. For instance, according to an article published by the Australian Government Department of Health in June 2020, the Australian government made an investment of AUD 29 million (US$ 22 million) under the Medical Research Future Fund’s (MRFF) Cardiovascular Health Mission. This was the first round of investment out of the total AUD 220 million (US$ 167 million) allotted for research in the management of cardiovascular diseases to prevent heart attack and stroke, which are the top most causes of death in Australia.

Global Cardiac Biomarkers Market - Impact of Coronavirus (COVID – 19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 177 million cases and 3.8 million deaths due to Coronavirus (COVID-19) were reported up till June 20, 2021 across the globe.

The COVID-19 pandemic has affected several markets across the globe by disrupting the supply chain of various industries such as biotechnology and healthcare industry. However, COVID-19 pandemic is expected to have a positive impact on the global cardiac biomarkers market as cardiovascular diseases are associated with COVID-19 disease.

According to an article published by the National Centers for Biotechnology Information in March 2021, it is expected that cardiac biomarkers would be used along with diagnostic markers for other organs for proper diagnosis and prognosis of COVID-19 infection. The same source confirmed that elevated levels of troponin were reported in COVID-19 patients worldwide. This study revealed that higher levels of cardiac biomarkers: NT-pro BNP and CK-MB were observed in severely affected COVID-19 patients and non-survivors of COVID-19 infection, this implies that higher levels of these cardiac biomarkers is associated with the worst outcomes. This is expected to drive the market growth of cardiac biomarkers as a diagnostic tool for better understanding of cardiovascular complications related to COVID-19 infection.

Browse 35 Market Data Tables and 30 Figures spread through 161 Pages and in-depth TOC on Global Cardiac Biomarkers Market, by Product Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), and Others), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), by Location of Testing (Laboratory Testing and Point-of-Care Testing), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Cardiac Biomarkers market, click the link below:

 https://www.coherentmarketinsights.com/market-insight/cardiac-biomarkers-market-4576

Moreover, business strategies such as collaborations is expected to drive the cardiac biomarkers market growth. For instance, according to Wiley Analytical Science magazine, in 2020, Thermo Fisher Scientific, an American research based healthcare services and scientific instrumentation provider, collaborated with the University of Nebraska Medical Center and AstraZeneca, a British-Swedish pharmaceutical company, to strengthen its clinical biomarkers product portfolio. This collaboration would help in discovery and development of novel biomarkers such as cardiac biomarkers for efficient characterization of clinical samples.

Key Takeaways of the Cardiac Biomarkers Market:

  • The global cardiac biomarkers market is expected to exhibit a CAGR of 10.40% over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028), owing to rising initiatives for cardiovascular disease management by government and private players.
  • For instance, in 2021, Amgen Inc., an American biotechnology company, collaborated with Familial hypercholesterolemia (FH) Foundation, Centers for Disease Control and Prevention (CDC) Foundation, the National Association of Chronic Disease Directors and Bayer Foundation to form an alliance in order to support the ‘million heart 2022’ initiative by CDC. The aim of million heart 2022 initiative is to prevent at least one million stroke and heart attacks by 2022. Such initiatives aid in driving the growth of cardiac biomarkers as they are used for the diagnosis of heart attacks and stroke.
  • Some of the major players operating in the global cardiac biomarkers market include Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher Corporation, Randox laboratories, Beckman Coulter, Siemens Healthcare, Becton, Dickinson and Company, BioMerieux, Creative Diagnostics, and Alere Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.